Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
69 stopped studies mapped to Gastric Carcinoma and descendants · 97% state a reason
Over the 69 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API ().
reasonMatches| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02862535 | Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in… | Phase 1 | terminated | Aug 11, 2016 | Gilead Sciences | Study was terminated due to sponsor's decision to not pursue further development of andecaliximab… | Sponsor / business decision |
| NCT03563352 | Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in… | — | withdrawn | Jun 20, 2018 | University of Southern California | Zero accrual | Enrollment / accrual |
| NCT02757391 | CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic… | Phase 1 | terminated | May 2, 2016 | M.D. Anderson Cancer Center | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | Phase 1 | terminated | May 21, 2019 | Seagen Inc. | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT03739801 | MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal… | Phase 1 / Phase 2 | withdrawn | Nov 14, 2018 | University of Southern California | PI left | Investigator |
| NCT02952989 | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | Phase 1 | terminated | Nov 2, 2016 | Seagen Inc. | Due to overall benefit/risk profile | Other (stated, no rule matched) |
| NCT03122548 | Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction… | Phase 2 | terminated | Apr 21, 2017 | Aduro Biotech, Inc. | Low enrollment and lack of clinical activity in other CRS-207 studies. | Enrollment / accrual |
| NCT00256321 | Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma | Phase 2 | terminated | Nov 21, 2005 | University of California, Irvine | Closed due to poor accrual | Enrollment / accrual |
| NCT02638909 | Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal… | Phase 2 | terminated | Dec 23, 2015 | Criterium, Inc. | Lack of Enrollment | Enrollment / accrual |
| NCT00848783 | Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed… | Phase 2 | terminated | Feb 20, 2009 | NYU Langone Health | Due to slow accrual | Enrollment / accrual |
| NCT02202759 | A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction | Phase 2 | terminated | Jul 29, 2014 | Millennium Pharmaceuticals, Inc. | Business Decision, No Safety or Efficacy Concerns | Safety / toxicity |
| NCT02391038 | MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma… | Phase 1 | terminated | Mar 18, 2015 | Millennium Pharmaceuticals, Inc. | The study was terminated because preliminary PK and overall clinical data demonstrated compelling… | Other (stated, no rule matched) |
| NCT00767234 | Permission to Collect Blood Over Time for Research | — | terminated | Oct 7, 2008 | Stanford University | Accrual issues - Low Accrual | Enrollment / accrual |
| NCT02334332 | Educational Brochure in Preparing Patients With Gastric Cancer and Their Caregivers for… | N/A | withdrawn | Jan 8, 2015 | City of Hope Medical Center | No accrual | Enrollment / accrual |
| NCT01989858 | ITACA-S2 (Intergroup Trial in Adjuvant Chemotherapy for Adenocarcinoma of the Stomach)(ITACA-S2) | Phase 3 | terminated | Nov 21, 2013 | Mario Negri Institute for Pharmacological Research | lack of clinical cases | Other (stated, no rule matched) |
| NCT01748851 | XELOX Versus FOLFOX for Advanced Gastric Cancer (AGC) | Phase 3 | terminated | Dec 13, 2012 | Dong-A University Hospital | Poor enrollment of patients | Enrollment / accrual |
| NCT01233505 | Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | Phase 1 | terminated | Nov 3, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00098527 | FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction… | Phase 2 | terminated | Dec 8, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01031056 | Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers | — | withdrawn | Dec 14, 2009 | Stanford University | Change in research focus | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Dec 24, 2020source: clinicaltrials